ADVANCE Phase 3 study confirms clinical great things about telaprevir regimen in patients with HCV infection The Stage 3 results from the ADVANCE study confirm the clinical great things about telaprevir-based combination therapy regimens. An improvement is reported by The analysis in treatment discontinuation rates because of adverse events compared to Phase 2 studies, and demonstrates a rise in sustained viral response in patients with hepatitis C virus generic drugs . The primary endpoint because of this scholarly study was SVR 24 weeks after last treatment. The scholarly research was conducted on 1088 treatment-naive HCV patients, all of whom got genotype 1. For the three arms of the trial, one group of patients was treated with 750 mg of telaprevir every eight hours in conjunction with peginterferon alfa-2a 180 ug/week and ribavirin 1000-1200 mg/day time for 12 weeks, as the second group was presented with the same treatment but for only eight weeks.
The WHO last week concluded the first meeting of a probe into its H1N1 response.This article is republished with kind permission from our friends at The Kaiser Family Foundation. You will see the complete Kaiser Daily Health Policy Statement, search the archives, or sign up for email delivery of in-depth coverage of health policy developments, debates and discussions. The Kaiser Daily Wellness Policy Report is published for Kaisernetwork.org, a free program of The Henry J. Kaiser Family Foundation. Copyright 2009 Advisory Board Firm and Kaiser Family Base.